Literature DB >> 12761109

Distribution and kinetics of lipoprotein-bound lipoteichoic acid.

Johannes H M Levels1, Philip R Abraham, Erik P van Barreveld, Joost C M Meijers, Sander J H van Deventer.   

Abstract

Lipoteichoic acid (LTA), a major cell wall component of gram-positive bacteria, is an amphipathic anionic glycolipid with structural similarities to lipopolysaccharide (LPS) from gram-negative bacteria. LTA has been implicated as one of the primary immunostimulatory components that may trigger the systemic inflammatory response syndrome. Plasma lipoproteins have been shown to sequester LPS, which results in attenuation of the host response to infection, but little is known about the LTA binding characteristics of plasma lipid particles. In this study, we have examined the LTA binding capacities and association kinetics of the major lipoprotein classes under simulated physiological conditions in human whole blood (ex vivo) by using biologically active, fluorescently labeled LTA and high-performance gel permeation chromatography. The average distribution of an LTA preparation from Staphylococcus aureus in whole blood from 10 human volunteers revealed that >95% of the LTA was associated with total plasma lipoproteins in the following proportions: high-density lipoprotein (HDL), 68% +/- 10%; low-density lipoprotein (LDL), 28% +/- 8%; and very low density lipoprotein (VLDL), 4% +/- 5%. The saturation capacity of lipoproteins for LTA was in excess of 150 micro g/ml. The LTA distribution was temperature dependent, with an optimal binding between 22 and 37 degrees C. The binding of LTA by lipoproteins was essentially complete within 10 min and was followed by a subsequent redistribution from HDL and VLDL to LDL. We conclude that HDL has the highest binding capacity for LTA and propose that the loading and redistribution of LTA among plasma lipoproteins is a specific process that closely resembles that previously described for LPS (J. H. M. Levels, P. R. Abraham, A. van den Ende, and S. J. H. van Deventer, Infect. Immun. 68:2821-2828, 2001).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761109      PMCID: PMC155762          DOI: 10.1128/IAI.71.6.3280-3284.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Distribution and kinetics of lipoprotein-bound endotoxin.

Authors:  J H Levels; P R Abraham; A van den Ende; S J van Deventer
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens.

Authors:  D M Underhill; A Ozinsky; A M Hajjar; A Stevens; C B Wilson; M Bassetti; A Aderem
Journal:  Nature       Date:  1999-10-21       Impact factor: 49.962

Review 3.  CD14 and LBP in endotoxemia and infections caused by Gram-negative bacteria.

Authors:  D Heumann
Journal:  J Endotoxin Res       Date:  2001

Review 4.  Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI.

Authors:  M Krieger
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

5.  Different binding of 125I-LPS to plasma proteins from persons with high or low HDL.

Authors:  J B Eggesbø; T Lyberg; T Aspelin; I Hjermann; P Kierulf
Journal:  Scand J Clin Lab Invest       Date:  1996-10       Impact factor: 1.713

6.  Interactions of bacterial lipopolysaccharide and peptidoglycan with a 70 kDa and an 80 kDa protein on the cell surface of CD14+ and CD14- cells.

Authors:  K Triantafilou; M Triantafilou; R L Dedrick
Journal:  Hum Immunol       Date:  2001-01       Impact factor: 2.850

7.  Characteristics of surfactant protein A and D binding to lipoteichoic acid and peptidoglycan, 2 major cell wall components of gram-positive bacteria.

Authors:  J K van de Wetering; M van Eijk; L M van Golde; T Hartung; J A van Strijp; J J Batenburg
Journal:  J Infect Dis       Date:  2001-10-12       Impact factor: 5.226

8.  Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from gram-negative bacterial membranes.

Authors:  C J Vesy; R L Kitchens; G Wolfbauer; J J Albers; R S Munford
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

9.  Lipoproteins inhibit macrophage activation by lipoteichoic acid.

Authors:  C Grunfeld; M Marshall; J K Shigenaga; A H Moser; P Tobias; K R Feingold
Journal:  J Lipid Res       Date:  1999-02       Impact factor: 5.922

10.  Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus.

Authors:  S Morath; A Geyer; T Hartung
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  39 in total

1.  HMGB1 Binds to Lipoteichoic Acid and Enhances TNF-α and IL-6 Production through HMGB1-Mediated Transfer of Lipoteichoic Acid to CD14 and TLR2.

Authors:  Man Sup Kwak; Mihwa Lim; Yong Joon Lee; Hyun Sook Lee; Young Hun Kim; Ju Ho Youn; Ji Eun Choi; Jeon-Soo Shin
Journal:  J Innate Immun       Date:  2015-02-05       Impact factor: 7.349

Review 2.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

3.  LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients.

Authors:  Auguste Dargent; Jean-Paul Pais de Barros; Samir Saheb; Randa Bittar; Wilfried Le Goff; Alain Carrié; Thomas Gautier; Isabelle Fournel; Anne Laure Rerole; Hélène Choubley; David Masson; Laurent Lagrost; Jean-Pierre Quenot
Journal:  J Lipid Res       Date:  2020-10-09       Impact factor: 5.922

4.  Blood-Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-Density Lipoprotein.

Authors:  Zhili Yao; Jessica M Mates; Alana M Cheplowitz; Lindsay P Hammer; Andrei Maiseyeu; Gary S Phillips; Mark D Wewers; Murugesan V S Rajaram; John M Robinson; Clark L Anderson; Latha P Ganesan
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

5.  PCSK9 is a critical regulator of the innate immune response and septic shock outcome.

Authors:  Keith R Walley; Katherine R Thain; James A Russell; Muredach P Reilly; Nuala J Meyer; Jane F Ferguson; Jason D Christie; Taka-aki Nakada; Chris D Fjell; Simone A Thair; Mihai S Cirstea; John H Boyd
Journal:  Sci Transl Med       Date:  2014-10-15       Impact factor: 17.956

6.  HDL and Sepsis.

Authors:  Huanhuan Cao; Wei Huang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

7.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.

Authors:  Sylvette Bas; Richard W James; Cem Gabay
Journal:  BMC Immunol       Date:  2010-09-16       Impact factor: 3.615

Review 8.  The Understanding and Management of Organism Toxicity in Septic Shock.

Authors:  Kelly Roveran Genga; Tadanaga Shimada; John H Boyd; Keith R Walley; James A Russell
Journal:  J Innate Immun       Date:  2018-05-15       Impact factor: 7.349

9.  Impact of the pre-illness lipid profile on sepsis mortality.

Authors:  Michael D Maile; Matthew J Sigakis; Kathleen A Stringer; Elizabeth S Jewell; Milo C Engoren
Journal:  J Crit Care       Date:  2020-01-14       Impact factor: 3.425

10.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.

Authors:  Matthew R Kimbrell; Hemamali Warshakoon; Jens R Cromer; Subbalakshmi Malladi; Jennifer D Hood; Rajalakshmi Balakrishna; Tandace A Scholdberg; Sunil A David
Journal:  Immunol Lett       Date:  2008-04-18       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.